Eccrine squamous syringometaplasia associated with vemurafenib therapy.
Scott G
SG
Story
Jonathan K
JK
Beschloss
Christopher K
CK
Dolan
Brian C
BC
Thomas
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D020405:Dermis / Q000473:pathology; D003875:Drug Eruptions / Q000209:etiology / Q000473:pathology*; D004439:Eccrine Glands / Q000473:pathology; D004890:Erythema / Q000139:chemically induced / Q000473:pathology; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy; D008679:Metaplasia; D012878:Skin Neoplasms / Q000188:drug therapy; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D013544:Sweat Gland Neoplasms / Q000473:pathology*; D018252:Syringoma / Q000473:pathology*; D000077484:Vemurafenib
D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib